


SONY

Accelerating discovery

Delivering innovation to transform your discoveries and advance human health



Learn more

#CYTO2022



Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity

Leon T. van den Broeke, Emily Daschbach, Elaine K. Thomas, Gerda Andringa and Jay A. Berzofsky

This information is current as of June 27, 2022.

J Immunol 2004; 173:695; ;
doi: 10.4049/jimmunol.173.1.695-b
<http://www.jimmunol.org/content/173/1/695.3>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

- Subscription** Information about subscribing to *The Journal of Immunology* is online at: <http://jimmunol.org/subscription>
- Permissions** Submit copyright permission requests at: <http://www.aai.org/About/Publications/JI/copyright.html>
- Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at: <http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2004 by The American Association of
Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



CORRECTIONS

Andreas Hombach, Anja Wiczarkowicz, Thomas Marquardt, Claudia Heuser, Loretta Usai, Christoph Pohl, Barbara Seliger, and Hinrich Abken. Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3 ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3 ζ Signaling Receptor Molecule. *The Journal of Immunology* 2001;167:6123–6131.

In *Materials and Methods*, the oligonucleotides number 1 and 2 given in Table I contain incorrect sequences. The correct table is shown below.

Table I. Oligonucleotide primers used for the generation of recombinant immunoreceptors

1-CD28 <i>Bam</i> HI-sense: 5'-CTGGATCCCAAATTTTGGGTGCTGGTGGTGGTTG-3' ^a
2-CD28- <i>Xho</i> I-antisense: 5'-CTACTCGAGGATCAGGAGCGATAGGCTGCGAA-3'
3-CD28-CD3 ζ -antisense: 5'-GTCTGCGCTCCTGCTGAACTTCACTCTCAGGGAGCGATAGGCTGCGAAGTC-3' ^b
4-CD28-CD3 ζ -sense: 5'-CCTATCGCTCCCTGAGAGTGAAGTTCAGCAGGAGC-3' ^b
5-CD ζ - <i>Xho</i> I-antisense: 5'-CTACTCGAGGATTAGCGAGGGGGCAGGGC-3'
6-L κ - <i>Nco</i> I-sense: 5'-CTACGTACCATGGATTTTCAGGTGCAGATTTTC-3'
7-hIgG1Fc- <i>Bgl</i> II-antisense: 5'-CCCACCCAGATCTTTTTTACCAGAGACAGGGAGAG-GCTCTCTG-3'

^aRestriction sites are underlined.

^bOverlapping sequences are in boldface.

Harnisha Dalwadi, Bo Wei, Matthew Schrage, Tom T. Su, David J. Rawlings, and Jonathan Braun. B Cell Developmental Requirement for the *Gai2* Gene. *The Journal of Immunology* 2003;170:1707–1715.

Karsten Spicher and Lutz Birnbaumer were inadvertently excluded from the author line. The correct listing is shown below.

Harnisha Dalwadi,* Bo Wei,* Matthew Schrage,* Karsten Spicher,† Tom T. Su,† Lutz Birnbaumer,§ David J. Rawlings,¶ and Jonathan Braun*†

*Department of Pathology and Laboratory Medicine and †Molecular Biology Institute, University of California, Los Angeles, CA 90095; ‡Institute of Pharmacology, Benjamin Franklin University, Berlin-Dahlem, Germany; §Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709; and ¶Departments of Pediatrics and Immunology, University of Washington, Seattle, WA 98195

In footnotes, the paper should credit the support of NIH DK19318 (to L.B.).

Leon T. van den Broeke, Emily Daschbach, Elaine K. Thomas, Gerda Andringa, and Jay A. Berzofsky. Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity. *The Journal of Immunology* 2003;171:5842–5852.

The authors regret that the credit shown below was inadvertently omitted from the footnotes.

We thank the G. Harold and Leila Y. Mathers Charitable Foundation for partial support of this research.